<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01045538</url>
  </required_header>
  <id_info>
    <org_study_id>AMC-ONCGI-0903</org_study_id>
    <nct_id>NCT01045538</nct_id>
  </id_info>
  <brief_title>Study of Vorinostat Plus Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer</brief_title>
  <acronym>Zolinza+XP</acronym>
  <official_title>A Phase I/II Study of Vorinostat (Zolinza®) in Combination With Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is scientific rationale for exploring the role of vorinostat, histone deacetylase
      inhibitor with capecitabine (X) and cisplatin (P), one of standard chemotherapy in patients
      with advanced gastric cancer. XP is a new standard of care in advanced gastric cancer (AGC)
      and vorinostat is a novel targeted agent that prevents tumor cell proliferation, survival and
      angiogenesis through histone deacetylase inhibition.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2010</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1 - maximum tolerated dose, Phase 2 - response rate</measure>
    <time_frame>3 weeks for maximum tolerated dose, and 6 months for response rate</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity profile</measure>
    <time_frame>toxicity for each cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>1 year</time_frame>
    <description>Time from first administration of study drug to disease progression or any cause of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
    <description>Time from first administration of study drug to any cause of death</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Histone Deacetylase Inhibitor</condition>
  <arm_group>
    <arm_group_label>Vorinostat plus XP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vorinostat 200~400mg per day on day1-day14 combined with capecitabine 800-1,000mg/m2/dose, BID on day1-day14, and cisplatin 60-80mg/m2 on day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vorinostat, capecitabine, and cisplatin</intervention_name>
    <description>Vorinostat 200~400mg per day on day1-day14 combined with capecitabine 800-1,000mg/m2/dose, BID on day1-day14, and cisplatin 60-80mg/m2 on day 1</description>
    <arm_group_label>Vorinostat plus XP</arm_group_label>
    <other_name>Zolinza, and xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed unresectable or metastatic advanced gastric adenocarcinoma

          -  Completion of adjuvant chemotherapy 6 months before the study, or no previous
             chemotherapy

          -  Age 18 to 70 years old

          -  Eastern Cooperative Oncology Group (ECOG) performance status 2 or less

          -  Estimated life expectancy of more than 3 months

          -  Presence of measurable or evaluable disease

          -  Adequate bone marrow function (ANC &gt;1,500/µL and platelets&gt;100,000/µL),

          -  Adequate renal function: creatinine &lt; 1 x upper normal limit (UNL) or creatinine
             clearance 60ml/min or less

          -  Adequate hepatic function: bilirubin &lt; 1.5 x UNL, aspartate aminotransferase
             (AST)/alanine aminotransferase (ALT) levels &lt; 2.5 x UNL (&lt; 5 x upper limit of normal
             for patients with liver involvement of their cancer), alkaline phosphatase &lt; 5 x UNL
             (except in case of bone metastasis without any liver disease)

          -  Written informed consent

        Exclusion Criteria:

          -  Prior exposure to any histone deacetylase (HDAC) inhibitor (however, valproic acid
             would be allowed if a 30-day wash-off period is provided.)

          -  Previous adjuvant treatment with capecitabine or platinums

          -  Contraindication to any drug contained in the chemotherapy regimen

          -  Other tumor type than adenocarcinoma

          -  Presence or history of central nervous system (CNS) metastasis

          -  Gastric outlet or bowel obstruction

          -  Evidence of serious gastrointestinal bleeding

          -  Peripheral neuropathy &gt; grade 2

          -  History of significant neurologic or psychiatric disorders

          -  History of another malignancy within the last five years except cured basal cell
             carcinoma of skin and cured carcinoma in-situ of uterine cervix

          -  Pregnant or lactating women, women of childbearing potential not employing adequate
             contraception

          -  Active human immunodeficiency virus (HIV) infection

          -  Viral hepatitis infections

          -  Other serious illness or medical conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Budman DR, Meropol NJ, Reigner B, Creaven PJ, Lichtman SM, Berghorn E, Behr J, Gordon RJ, Osterwalder B, Griffin T. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol. 1998 May;16(5):1795-802.</citation>
    <PMID>9586893</PMID>
  </reference>
  <reference>
    <citation>Cassidy J, Dirix L, Bissett D, Reigner B, Griffin T, Allman D, Osterwalder B, Van Oosterom AT. A Phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors. Clin Cancer Res. 1998 Nov;4(11):2755-61.</citation>
    <PMID>9829739</PMID>
  </reference>
  <reference>
    <citation>Glimelius B, Ekström K, Hoffman K, Graf W, Sjödén PO, Haglund U, Svensson C, Enander LK, Linné T, Sellström H, Heuman R. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997 Feb;8(2):163-8.</citation>
    <PMID>9093725</PMID>
  </reference>
  <reference>
    <citation>Hansen RM. 5-Fluorouracil by protracted venous infusion: a review of recent clinical studies. Cancer Invest. 1991;9(6):637-42.</citation>
    <PMID>1747791</PMID>
  </reference>
  <reference>
    <citation>Hong YS, Song SY, Lee SI, Chung HC, Choi SH, Noh SH, Park JN, Han JY, Kang JH, Lee KS, Cho JY. A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann Oncol. 2004 Sep;15(9):1344-7.</citation>
    <PMID>15319239</PMID>
  </reference>
  <reference>
    <citation>Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, Kang YK, Shin DB, Kim HT, Kim HJ, et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer. 1993 Jun 15;71(12):3813-8.</citation>
    <PMID>8508349</PMID>
  </reference>
  <reference>
    <citation>Kim TW, Kang YK, Ahn JH, Chang HM, Yook JH, Oh ST, Kim BS, Lee JS. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. Ann Oncol. 2002 Dec;13(12):1893-8.</citation>
    <PMID>12453857</PMID>
  </reference>
  <reference>
    <citation>Koizumi W, Saigenji K, Ujiie S, Terashima M, Sakata Y, Taguchi T; Clinical Study Group of Capecitabine. A pilot phase II study of capecitabine in advanced or recurrent gastric cancer. Oncology. 2003;64(3):232-6.</citation>
    <PMID>12697963</PMID>
  </reference>
  <reference>
    <citation>Kurdistani SK. Histone modifications as markers of cancer prognosis: a cellular view. Br J Cancer. 2007 Jul 2;97(1):1-5. Epub 2007 Jun 26. Review.</citation>
    <PMID>17592497</PMID>
  </reference>
  <reference>
    <citation>Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007 Oct;12(10):1247-52.</citation>
    <PMID>17962618</PMID>
  </reference>
  <reference>
    <citation>Park YS, Jin MY, Kim YJ, Yook JH, Kim BS, Jang SJ. The global histone modification pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma. Ann Surg Oncol. 2008 Jul;15(7):1968-76. doi: 10.1245/s10434-008-9927-9. Epub 2008 May 10.</citation>
    <PMID>18470569</PMID>
  </reference>
  <reference>
    <citation>Weichert W, Röske A, Gekeler V, Beckers T, Ebert MP, Pross M, Dietel M, Denkert C, Röcken C. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol. 2008 Feb;9(2):139-48. doi: 10.1016/S1470-2045(08)70004-4.</citation>
    <PMID>18207460</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2010</study_first_submitted>
  <study_first_submitted_qc>January 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2010</study_first_posted>
  <last_update_submitted>July 13, 2017</last_update_submitted>
  <last_update_submitted_qc>July 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Yoon-Koo Kang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>gastric cancer</keyword>
  <keyword>histone deacetylase inhibitor</keyword>
  <keyword>1st line chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vorinostat</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Histone Deacetylase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

